Clinical Trial Update: Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and impact of dasatinib on HIV viral persistence and inflammation in people on antiretroviral therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Fundació Institut Germans Trias i Pujol | Conditions: HIV Infection Primary | Phase 2 | Status: COMPLETED